Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia, Actos Add Black Box; RECORD Leaves Heart Attack Risk Unresolved

Executive Summary

FDA is adding a "black box" warning about the risk of congestive heart failure to thiazolidinediones while it continues to evaluate the potential risk of myocardial infarction seen in the class of type 2 diabetes therapies

You may also be interested in...



Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health

Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years

Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health

Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years

Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads

FDA has unveiled the much-anticipated labeling change for GlaxoSmithKline's type 2 diabetes therapy Avandia, but is deeming the information about rosiglitzone's cardiovascular risk "inconclusive" and is asking the sponsor to undertake a long-term outcomes study to address outstanding safety questions

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel